Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...